{"id":"NCT01008423","sponsor":"Bausch Health Americas, Inc.","briefTitle":"Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis","officialTitle":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Budesonide Foam (2 mg/25 mL BID for 2 Weeks, Followed by 2 mg/25 mL QD for 4 Weeks) Versus Placebo in Subjects With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-11-20","primaryCompletion":"2013-03-18","completion":"2013-03-18","firstPosted":"2009-11-05","resultsPosted":"2019-08-14","lastUpdate":"2019-08-14"},"enrollment":281,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Proctitis","Proctosigmoiditis"],"interventions":[{"type":"DRUG","name":"Budesonide","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Budesonide","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to establish the efficacy profile of rectally administered budesonide foam, as compared to an equivalent volume of rectally administered placebo foam over the same dosing schedule, in participants who present with a diagnosis of active, mild to moderate, ulcerative proctitis (UP) or ulcerative proctosigmoiditis (UPS). During the study, eligible participants will be allowed to maintain previously established oral 5-aminosalicylic acid (5-ASA) treatment at doses up to 4.8 grams/day (g/day).","primaryOutcome":{"measure":"Percentage of Participants Who Achieved Remission","timeFrame":"Week 6","effectByArm":[{"arm":"Budesonide","deltaMin":44,"sd":null},{"arm":"Placebo","deltaMin":22.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":22},"locations":{"siteCount":62,"countries":["United States"]},"refs":{"pmids":["27416045","25644096"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":134},"commonTop":["Blood cortisol decreased","Headache","Urinary tract infection","Abdominal pain","Nasopharyngitis"]}}